Amyloidosis: the use of the Daratumumab

Open Access

1 December 2020

journal article
editorial
Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira

Vol. 66 (12), 1620
https://doi.org/10.1590/1806-9282.66.12.1620

Abstract

ANSWER: The use of daratumumab in patients with clinical symptoms of amyloidosis currently should not be recommended due to the weakness of the evidence available to support it. ¹

Keywords

WEAKNESS
ANSWER
SUP
AMYLOIDOSIS
USE OF DARATUMUMAB
RECOMMENDED DUE
CLINICAL SYMPTOMS
DARATUMUMAB IN PATIENTS

This publication has 1 reference indexed in Scilit:

Use of daratumumab in patients with amyloidosis
Revista da Associação Médica Brasileira, 2020